You just read:

Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status

News provided by

Jazz Pharmaceuticals plc

May 31, 2017, 16:05 ET